Extracellular HSP90 interacts with LRP1 (also known as CD91) to induce ERK and MMP-2/9 activation, leading to E-cadherin inhibition and the initiation of EMT in prostate cancer cells (51, 151). Here, LRP1 is linked to prostate cancer.